These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28856784)

  • 41. Pharmacotherapy of onychomycosis.
    Baran R; Gupta AK; Piérard GE
    Expert Opin Pharmacother; 2005 Apr; 6(4):609-24. PubMed ID: 15934887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Onychomycosis.
    Zaraa I; Dehavay F; Richert B
    Hand Surg Rehabil; 2024 Apr; 43S():101638. PubMed ID: 38218374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topical and oral combination therapy for toenail onychomycosis: an updated review.
    Bristow IR; Baran R
    J Am Podiatr Med Assoc; 2006; 96(2):116-9. PubMed ID: 16546948
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diversified treatments of Tinea unguium].
    Fukuda T
    Nihon Ishinkin Gakkai Zasshi; 2002; 43(2):85-9. PubMed ID: 12040365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preventing complications in the diabetic patient with toenail onychomycosis.
    Anarella JJ; Toth C; DeBello JA
    J Am Podiatr Med Assoc; 2001 Jun; 91(6):325-8. PubMed ID: 11420354
    [No Abstract]   [Full Text] [Related]  

  • 46. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail.
    Jones HE; Zaias N
    Int J Dermatol; 1996 Aug; 35(8):589-90. PubMed ID: 8854164
    [No Abstract]   [Full Text] [Related]  

  • 47. Oral terbinafine treatment for toenail onychomycosis: follow-up after 5-6 years.
    Molin L; Tarstedt M; Engman C
    Br J Dermatol; 2000 Sep; 143(3):682-3. PubMed ID: 10971374
    [No Abstract]   [Full Text] [Related]  

  • 48. Onychomycosis: current treatment and future challenges.
    Roberts DT
    Br J Dermatol; 1999 Nov; 141 Suppl 56():1-4. PubMed ID: 10730907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis.
    Firooz A; Khamesipour A; Dowlati Y
    J Dermatolog Treat; 2003 Jun; 14(2):95-8. PubMed ID: 12775316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation.
    Schaller M; Walker B; Nabhani S; Odon A; Riel S; Jäckel A
    Mycoses; 2024 Mar; 67(3):e13710. PubMed ID: 38414346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of outcome in the treatment of onychomycosis.
    Sommer S; Sheehan-Dare RA; Goodfield MJ; Evans EG
    Clin Exp Dermatol; 2003 Jul; 28(4):425-8. PubMed ID: 12823307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutropenia and pancytopenia associated with oral terbinafine.
    Kovacs MJ; Alshammari S; Guenther L; Bourcier M
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):806. PubMed ID: 7929931
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents.
    Gupta AK; Elewski B; Joseph WS; Lipner SR; Daniel CR; Tosti A; Guenin E; Ghannoum M
    Mycoses; 2024 Jan; 67(1):e13683. PubMed ID: 38214375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine.
    Zaias N; Serrano L
    Clin Exp Dermatol; 1989 Mar; 14(2):120-3. PubMed ID: 2532084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapy of onychomycosis].
    Reisberger EM; Szeimies RM
    Med Klin (Munich); 2000 Nov; 95(11):618-28. PubMed ID: 11143542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single dose treatment of fungal nail disease.
    Shuster S; Munro CS
    Lancet; 1992 Apr; 339(8800):1066. PubMed ID: 1349100
    [No Abstract]   [Full Text] [Related]  

  • 57. [Study on the compliance and safety of the oral antifungal agents for the treatment of onychomycosis].
    Hu Y; Yang LJ; Wei L; Dai XY; Hua HK; Qi J; Sun H; Zheng Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Dec; 26(12):988-91. PubMed ID: 16676597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute generalized exanthematous pustulosis associated with oral terbinafine.
    Hall AP; Tate B
    Australas J Dermatol; 2000 Feb; 41(1):42-5. PubMed ID: 10715900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical treatments for onychomycosis: a historical perspective.
    Bodman MA; Feder L; Nace AM
    J Am Podiatr Med Assoc; 2003; 93(2):136-41. PubMed ID: 12644521
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reversible agranulocytosis associated with oral terbinafine for onychomycosis.
    Ornstein DL; Ely P
    J Am Acad Dermatol; 1998 Dec; 39(6):1023-4. PubMed ID: 9843023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.